RHEUMATOID ARTHRITIS DIAGNOSTIC TESTS MARKET ANALYSIS

The global rheumatoid arthritis diagnostic tests market is estimated to be valued at US$ 2,775.1 million in 2023 and is expected to exhibit a CAGR of 5.4% during the forecast period (2023-2030).

Analysts’ Views on Global Rheumatoid Arthritis Diagnostic Tests Market:

Increasing prevalence of rheumatoid arthritis, rising geratic population and increasing awareness about rheumatoid arthritis, new product releases and strategic efforts by prominent market competitors are favorably impacting the industry's growth. The high prevalence of rheumatoid arthritis, favorable health reimbursement, and increased awareness regarding Rheumatoid arthritis among people and clinicians is a major factor in the rheumatoid arthritis diagnostic tests market, thereby contributing to market growth.

Figure 1. Global Rheumatoid Arthritis Diagnostic Tests Market Share (%),By Test Type, 2023

To learn more about this report, Request sample copy

Global Rheumatoid Arthritis Diagnostic Tests Market – Driver

Increasing prevalence of rheumatoid arthritis

Increasing prevalence of rheumatoid arthritis is expected to propel growth of the global rheumatoid arthritis diagnostic tests market over the forecast period. For instance, according to the article published in National Libarary of medicine Journal in September 2022, reported the age-standardized point prevalence and annual incidence rates of  rheumatoid arthritis were 446.6 and 24.9 in 2021, which increased by 12.4% and 9.9% from 2001, respectively.

Increasing expenditure for the treatment and management of rheumatoid arthritis

Increasing expenditure for the treatment and management of RA is also expected to aid in growth of the market. For instance, according to the study published in the journal PLOS One in October 2021, reported “Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis ”, the annual health expenditures were significantly larger for patients with rheumatoid arthritis than for controls.

Figure 2. Global Rheumatoid Arthritis Diagnostic Tests Market Value (US$ Million), by Region, 2023

To learn more about this report, Request sample copy

Global Rheumatoid Arthritis Diagnostic Tests Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global rheumatoid arthritis diagnostic tests market over the forecast period. North America is estimated to hold 39.45 % of the market share in 2023. The global rheumatoid arthritis diagnostic tests market is expected to witness significant growth in the coming years, Driven by the high prevalence of rheumatoid arthritis, favorable health reimbursement, and increased awareness, North America to emerge as the leading region for the rheumatoid arthritis diagnostic test market. According to the Centers for Disease Control and Prevention, the projected prevalence of the U.S. adults reported doctor-diagnosed arthritis report in 2020 seems to be 63 million. This region's rise can be related to a spike in arthritis in the U.S. and the rest of North America. For instance, according to the press release in February 2020, by imaware provides laboratory testing for wellness monitoring, informational, and educational use in North America., announced the launch of the At-Home Rheumatoid Arthritis Screening Test, designed by healthcare company Micro drop. The imaware test for Rheumatoid Arthritis uses just a few drops of blood to detect unique biomarkers as well as two additional biomarkers to provide more comprehensive results. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced rheumatoid arthritis treatments, are fueling the rheumatoid arthritis market in North America.

Global Rheumatoid Arthritis Diagnostic Tests Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of things from one place to another.

However, the COVID-19 pandemic had a positive impact on the global rheumatoid arthritis diagnostic tests market. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of rheumatoid arthritis patients increased, and so has the demand for the rheumatoid arthritis diagnostic test market. For instance, According to the article published in 2021 on PubMed Central, “COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges” explains that the management of rheumatoid arthritis patients in the COVID-19 context is a difficult task in and of itself. Even though online consultations are advisable with patients who are having stable rheumatoid arthritis.

Global Rheumatoid Arthritis Diagnostic Tests Market Segmentation:

The Global Rheumatoid Arthritis Diagnostic Tests Market report is segmented into by Test Type, By End User and Region.

By Test Type , the market is segmented into Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests), Monitoring RA Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test) out of which, the  into Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests) is expected to hold a dominant position in the global rheumatoid arthritis diagnostic tests market during the forecast period and this is attributed to awareness of rhumetoid arthritis.

By End User , the market is segmented into diagnostic laboratories, private laboratories, public laboratories, ambulatory surgical centers. out of which, the diagnostic laboratories is expected to dominate the market over the forecast period and this is attributed to the early diagnostic tests and prompt treatment can lead to proper recovery.

Among all the segmentations, the End user segment expected to dominate the market over the forecast period and this is attributed to the properly detecting rheumatoid arthritis is rheumatoid arthritis diagnostic tests market over the forecast period.

Global Rheumatoid Arthritis Diagnostic Tests Market Cross Sectional Analysis:

Key players are making rheumatoid arthritis diagnostic tests with advance technology emerging economies is also expected to boost demand Rheumatoid Arthritis Diagnostic Tests market in North America region. For instance, in October 2020, Quest Diagnostics, is the provider of diagnostic information services in New York, U.S, announced the availability of two new blood tests with advance technology new variant of test for aiding the early diagnosis of rheumatoid arthritis (RA), an autoimmune disorder that can cause debilitating joint damage.

Global Rheumatoid Arthritis Diagnostic Tests Market: Key Developments

In April 2022, Specialty Networks, LLC, a portfolio company of Linden Capital Partners is an integrated, multi-specialty organization with GPOs, Life Sciences, and Research solutions in U.S., announced the acquisition of United Rheumatology, LLC is the Rheumatology group purchasing organization (GPO) and real-world evidence (RWE) data & analytics company, community Rheumatology clinics will be able to maintain their independence while also improving the standard of treatment for patients.

In May 2021, the Arthritis Foundation is the nonprofit organization dedicated to the prevention control and cure of America's leading cause of rheumatoid arthritis, announced the launch of a application (Vim, the Arthritis Foundation's mobile app) and kicks off Arthritis Awareness with the release of key findings from a patient study.

In May 2022, United Rheumatology is the rheumatology care management organization empowering rheumatologists to advance the standard of care and CreakyJoints is a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease, announced a partnership to develop the Rheumatoid Arthritis Wellness Center, a digital resource aimed at aiding those living with rheumatoid arthritis.

In September 2021, Labcorp is a life sciences company based in the U.S., announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay.

Global Rheumatoid Arthritis Diagnostic Tests Market: Key Trends

Application of biomarker test for diagnosing rheumatoid arthritis

Application of biomarker test for diagnosing rheumatoid arthritis is at an early stage of development. Major players in the market are focused on adopting partnership strategies to expand their product portfolio. Presently, there is no biochemical test available for the diagnosis of RA. However, Rheumatoid Factor (RF) and Anti–Cyclic Citrullinated Peptide (anti–CCP) antibodies test require more refinement to improve their clinical utility. For instance, in March 2020, WorldCare Clinical, LLC, an independent CRO offering imaging in clinical trials partnesred with Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals to offer imaging service following FDA approval of Navidea’s RA diagnostic.

Global Rheumatoid Arthritis Diagnostic Tests Market: Restraint

Limited specificity and sensitivity of test kits

Limited specificity and sensitivity of test kits available in the market is expected to hinder growth of the global rheumatoid arthritis diagnostic tests market. For instance, according to article published in biomedical phamcology journal in may 2021, reported determination of specificity and sensitivity of rheumatoid factor and anti ccp tests in patients with ra in private clinic in Tehran. 110 individuals out of RA group (25.7%) were Anti-CCP negative and the others (74.3%) were positive. While 375 individuals out of non-RA group (92.8%) were Anti-CCP negative and the others (7.2%) were positive.

Key players focusing on developing technologically advanced test kits which is expected to drive the market growth over the forecast period

Global Rheumatoid Arthritis Diagnostic Tests Market - Key Players

Major players operating in the global rheumatoid arthritis diagnostic tests market include Abbott Diagnostics (Abbott Laboratories), Labcorp ,Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB,  and  Thermo Fisher Scientific Inc.

Definition: Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in your body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees